Novartis and Molecular Partners Report Inclusion of Ensovibep (MP0420) in NIH-Sponsored ACTIV-3 Trial for the Treatment of COVID 19

 Novartis and Molecular Partners Report Inclusion of Ensovibep (MP0420) in NIH-Sponsored ACTIV-3 Trial for the Treatment of COVID 19

Novartis and Molecular Partners Report Inclusion of Ensovibep (MP0420) in NIH-Sponsored ACTIV-3 Trial for the Treatment of COVID 19

Shots:

  • The P-III ACTIV-3 trial plan to evaluate the safety & efficacy of Ensovibep (MP0420) vs PBO in 300 patients hospitalized with mild to moderate COVID-19. The first patient dosing is anticipated in Q2’21
  • If the ensovibep treatment has a positive benefit/risk profile, the trial will enroll an additional 700 patients. Ensovibep is currently being evaluated in a P-I study and its data supports safety, tolerability and 2-3wks. the half-life of the therapy
  • Additionally, the companies plan to initiate a global P- II/III EMPATHY study of Ensovibep in Q2’21. The study will enroll 2,000+ patients in the ambulatory setting

Click here ­to­ read full press release/ article | Ref: Molecular Partners | Image: Swiss Biotech Association

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post